

January 4, 2018



Syros to Present at 36th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2018 objectives, at the 36th Annual J.P. Morgan Healthcare Conference. Details are as follows:

36th Annual J.P. Morgan Healthcare Conference

Date: Thursday, January 11

Time: 10:30 a.m. PST (1:30 p.m. EST)

Location: Westin St. Francis Hotel, 335 Powell St., San Francisco, CA

The presentation will be followed by a question and answer session.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RAR α agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20180104005470/en/>

Media:

Syros Pharmaceuticals

Naomi Aoki, 617-283-4298

naoki@syros.com

or

Investors:

Stern Investor Relations, Inc.

Hannah Deresiewicz, 212-362-1200

hannahd@sternir.com

Source: Syros Pharmaceuticals